Loading...
XETR
EUZ
Market cap395mUSD
Jun 27, Last price  
67.85EUR
1D
1.13%
1Q
21.64%
Jan 2017
891.11%
IPO
2,734.75%
Name

Eckert & Ziegler Strahlen und Medizintechnik AG

Chart & Performance

D1W1MN
P/E
13.06
P/S
1.40
EPS
5.19
Div Yield, %
0.82%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
7.84%
Revenues
246m
+10.72%
35,533,00041,792,0000071,612,000101,399,000111,093,000116,197,000119,997,000117,138,000127,256,000140,046,000137,935,000138,631,000168,709,000178,493,000176,140,000180,435,000222,260,000246,092,000
Net income
26m
-10.17%
3,426,0001,590,000003,037,00021,892,00010,415,00011,415,00010,293,0009,089,0006,775,00010,718,0009,550,00014,701,00016,133,00022,019,00021,287,00034,527,00029,278,00026,300,000
CFO
47m
+36.88%
2,559,0003,531,0006,919,0008,291,0008,566,00022,112,00015,025,00020,159,00016,574,00014,649,00010,653,00016,230,00019,832,00026,827,00021,210,00040,429,00036,787,00033,855,00034,298,00046,947,000
Dividend
Jun 19, 20250 EUR/sh
Earnings
Aug 07, 2025

Profile

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
URL
https://www.ezag.com/
IPO date
Feb 25, 2008
Employees
1,036
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
246,092
10.72%
222,260
23.18%
Cost of revenue
158,835
142,326
Unusual Expense (Income)
NOPBT
87,257
79,934
NOPBT Margin
35.46%
35.96%
Operating Taxes
11,824
13,256
Tax Rate
13.55%
16.58%
NOPAT
75,433
66,678
Net income
26,300
-10.17%
29,278
-15.20%
Dividends
(10,406)
(10,382)
Dividend yield
Proceeds from repurchase of equity
149
BB yield
Debt
Debt current
8,948
2,690
Long-term debt
77,272
74,084
Deferred revenue
2,005
2,250
Other long-term liabilities
80,895
82,945
Net debt
(13,889)
(20,139)
Cash flow
Cash from operating activities
46,947
34,298
CAPEX
(26,276)
(31,130)
Cash from investing activities
(42,745)
(41,043)
Cash from financing activities
(9,283)
(5,707)
FCF
15,530
30,796
Balance
Cash
67,998
82,701
Long term investments
32,111
14,212
Excess cash
87,804
85,800
Stockholders' equity
160,468
150,592
Invested Capital
275,493
257,574
ROIC
28.30%
29.94%
ROCE
23.93%
22.94%
EV
Common stock shares outstanding
20,824
20,798
Price
Market cap
EV
EBITDA
100,631
90,914
EV/EBITDA
Interest
3,993
1,773
Interest/NOPBT
4.58%
2.22%